REVIEW ARTICLE https:/doi.org/10.3126/njms.v10i2.79012

Synergistic Approaches in Diabetes Management: The Role of Anti-Diabetic Drugs and Herbal Medicine in Therapeutic Strategies

Ebadi AG

Researcher and Faculty member, Department of Natural Resources, Jo.C, Islamic Azad University, Jouybar, Iran

Received: February 26, 2025 **Accepted: June 16, 2025** **Published: June 30, 2025**

Cite this paper: Ebadi AG, Synergistic Approaches in Diabetes Management: The Role of Anti-Diabetic Drugs and Herbal Medicine in Therapeutic Strategies, *Nepal Journal of Medical Sciences*, 2025;10(2):19:68-82. https:/doi.org/10.3126/njms.v10i2.79012

Corresponding Author: Abdol Ghaffar Ebadi, Department of Natural Resources, Jo.C, Islamic Azad University, Jouybar, Iran. Email: abdolghaffar.ebadi@iau.ac.ir; dr_ebadi2000@yahoo.com

ABSTRACT

Diabetes mellitus remains a major global health issue that needs new and multi-dimensional therapeutic approaches to achieve maximum glycemic control with minimum side effects. Conventional anti-diabetic drugs, including insulin, biguanides, sulfonylureas, DPP-4 inhibitors, and SGLT2 inhibitors, have been well established to efficiently manage blood glucose levels but are typically encumbered with drug resistance, side effects, and long-term issues. Thus, there has been a growing tendency towards the use of herbal medicine as an adjunct approach for enhancing diabetes management. Among the medicinal plants such as Berberis vulgaris, Curcuma longa, *Momordica charantia*, *Trigonella foenum-graecum*, *Gymnema sylvestre*, and *Panax ginseng*, some possess strong anti-hyperglycemic, insulin-sensitizing, and antioxidant properties. These bioactive compounds regulate glucose metabolism through diverse mechanisms, including enhanced insulin release, improved insulin sensitivity, inhibition of glucose absorption, and regulation of oxidative stress and inflammation. Present research highlights the synergistic potential of the coadministration of concomitant pharmaceutical drugs with herbal remedy for achieving greater therapeutic efficacy, reducing drug dependence, and preventing adverse effects. However, while promising preclinical and clinical studies exist, problems remain regarding pharmacokinetic interactions, quality control of herbal extracts, and regulatory approval. This review critically evaluates mechanisms, benefits, and safety consequences of drug-herb synergy in the treatment of diabetes and bridges knowledge gaps. Directions for future research call for personalized medicine, novel drug delivery systems, and rigorous clinical trials to verify the therapeutic benefits of integrative therapy. Implying the synergy of herbal medicine with anti-diabetic drugs can pave the way for more effective, cleaner, and greener methods of combating diabetes and its complications.

Keywords: *Diabetes mellitus; Anti-diabetic drugs; Herbal medicine; Insulin resistance; Glycemic control.*

INTRODUCTION

Diabetes mellitus, a common chronic illness, is characterized by an elevated level of blood glucose for an extended period of time due to impaired insulin secretion or insulin resistance. According to International Diabetes Federation (2021), approximately 537 million adults lived with diabetes worldwide in 2021, and it will surpass 700 million by 2045. Diabetes, particularly type 2 diabetes (T2D), is a major risk factor for the majority of complications like cardiovascular diseases, neuropathy, nephropathy, and retinopathy, which have profound implications for quality of life and health system use [1]. Further, rising diabetes prevalence is irrevocably intertwined with lifestyle shifts, urban living, inappropriate food intake, and lack of exercise, highlighting the need to plan efficient management regimes.

The medical management of diabetes typically involves a combination of lifestyle interventions—such as dietary modification and physical activity—and pharmacological treatment with oral anti-diabetic drugs (OADs) and insulin. However, long-term reliance on conventional pharmacological therapies may lead to adverse effects including hypoglycemia, gastrointestinal disturbances, weight gain, and eventually drug resistance, all of which complicate effective disease control (2). In an effort to overcome these limitations, there is increasing interest in integrating herbal medicine as a complementary approach to conventional therapy. Herbal medicines have been used for centuries across diverse cultures due to their potential therapeutic properties, such as anti-hyperglycemic, anti-inflammatory, and antioxidant effects. Several botanicals, including cinnamon, ginseng, and berberine, have demonstrated the ability to lower blood glucose levels, enhance insulin sensitivity, and mitigate diabetes-related complications, often with fewer side effects than standard pharmacological agents (3). Table 1 presents a summary of key findings from previous studies investigating the concurrent use of anti-diabetic drugs and herbal medicines. The data highlight the potential benefits of combined therapy, including improved glycemic control, enhanced insulin responsiveness, and a reduction in treatment-related adverse effects. The table includes the names of specific herbs and anti-diabetic medications used in each study, the outcomes observed, and the overall effectiveness of the combined interventions in managing both blood glucose levels and diabetic complications.

This review comprehensively investigates the therapeutic potential and clinical relevance of co-administering anti-diabetic pharmaceutical agents with herbal remedies as an integrative, multi-targeted strategy for diabetes management. It aims not only to assess the pharmacodynamic and pharmacokinetic interactions between conventional drugs and medicinal plants, but also to elucidate the underlying molecular mechanisms through which such combinations exert anti-hyperglycemic, insulin-sensitizing, anti-inflammatory, and antioxidant effects. Furthermore, the review systematically evaluates the current body of preclinical and clinical evidence supporting the efficacy and safety of drug-herb synergy in diabetes treatment. By highlighting the therapeutic advantages—such as improved glycemic control, reduced drug dosages, minimized adverse effects, and potential delay in disease progression—this review underscores the clinical promise of integrated treatment approaches. Finally, it identifies critical gaps in existing research and provides direction for

future studies, including the need for well-designed randomized controlled trials, standardization of herbal formulations, and exploration of personalized treatment models. In doing so, this work contributes to the growing body of literature advocating for evidence-based, patient-centered approaches in modern diabetes care.

Table 1: Summary of Synergistic Effects of Herbal Medicine and Anti-Diabetic Drugs in Diabetes Management

Study	Therapeutic Approach	Anti-Diabetic Drug(s)	Herbal Treatment Used	Key Findings	Outcome
[4]	Systematic Review	Metformin, Glibenclamide	Cinnamon, Ginseng, Berberine	Combination of anti-diabetic drugs and herbal medicine improves glycemic control and reduces side effects.	Significant reduction in HbA1c, improved insulin sensitivity.
[5]	Randomized Controlled Trial	Metformin	Bitter melon, *Gymnema sylvestre*	Combination therapy leads to better glycemic control compared to monotherapy.	Lower blood glucose levels, reduced insulin resistance.
[6]	Clinical Trial	Pioglitazone, Metformin	Turmeric, Green Tea Extract	Synergistic effects in managing T2D with reduced dose of pharmaceutical drugs.	Enhanced antioxidant effects, better glucose control, fewer side effects.
[7]	Meta-analysis	Insulin, Glimepiride	Aloe Vera, Fenugreek, Berberine	Herbs reduce inflammation and improve glycemic regulation, supporting drug efficacy.	Decreased blood glucose and inflammatory markers.

[8]	Preclinical Study	Glibenclamide, Pioglitazone	Garlic, Fenugreek, Berberine	Herbal drugs potentiate the effect of anti-diabetic drugs.	Enhanced pancreatic beta-cell function, improved glucose metabolism.
[9]	Clinical Trial	Glibenclamide, Metformin	Olive leaf extract, Turmeric	Reduced adverse effects of diabetes drugs when used in combination with herbal treatments.	Better long-term control of blood glucose, reduced gastrointestinal side effects.

PATHOPHYSIOLOGY OF DIABETES MELLITUS

Diabetes mellitus, type 2 diabetes as well as type 1 diabetes, is a multifactorial disorder with varying pathophysiologies underlying. Type 1 diabetes (T1D) is an autoimmune destruction of pancreatic β-cells leading to an absolute deficiency of insulin [10]. On the other hand, type 2 diabetes (T2D) is predominantly due to insulin resistance, where target tissues such as muscle, liver, and fat fail to respond to insulin, and also impaired insulin secretion due to β-cell dysfunction [11]. Insulin resistance in T2D is typically augmented by obesity, inflammation, and genetic predisposition [12].

Oxidative stress plays a central role in the pathogenesis and development of both types of diabetes. Hyperglycemia enhances the production of reactive oxygen species (ROS), which in turn lead to further cellular and tissue damage, particularly to the vasculature, kidneys, nerves, and retina [13]. The oxidative stress leads to endothelial dysfunction, resulting in complications such as diabetic retinopathy, nephropathy, and neuropathy [14]. Furthermore, elevated blood glucose disrupts the proper functioning of β-cells, resulting in a vicious cycle of insulin dysfunction and resistance [15]. With disease progression, depletion of β-cells and chronic hyperglycemia result in worsening of diabetes complications, highlighting the need for early intervention in both types of diabetes management [16]. Pathophysiology of diabetes is a complex interplay of genetic, environmental, and metabolic factors that finally result in deranged glucose homeostasis that affects the entire body. The mechanisms underlying such events are responsible for developing effective therapy (Figure 1).



Figure 1: Blood Glucose Levels over Time for Healthy Individuals vs. Type 2 Diabetes.

Figure 1 illustrates the distinct patterns of blood glucose regulation in normal versus type 2 diabetic individuals over an 8-hour postprandial period (i.e., following food intake). In healthy

individuals, blood glucose levels remain relatively stable, peaking modestly at approximately 130 mg/dL and then gradually returning to baseline, reflecting an effective insulin response. In contrast, individuals with type 2 diabetes exhibit a higher fasting baseline glucose level (around 120 mg/dL) and a pronounced rise after eating, reaching up to 260 mg/dL within 8 hours. This marked elevation indicates insulin resistance and impaired pancreatic β-cell function, resulting in ineffective glucose regulation. The significant divergence between the two profiles underscores the critical need for effective management of type 2 diabetes to mitigate the risk of chronic complications, including cardiovascular disease and organ damage.

Table 2. Comparison of Blood Glucose Reduction Over Time by Conventional Anti-Diabetic Drugs

Time (hours)	Insulin Therapy (mg/dL)	Metformin (mg/dL)	Sulfonylureas (mg/dL)	DPP-4 Inhibitors (mg/dL)	SGLT2 Inhibitors (mg/dL)	Thiazolidinediones (mg/dL)
0	100	105	110	108	115	110
2	110	115	120	112	125	120
4	120	125	130	118	130	128
6	130	135	140	123	138	135
8	140	145	150	130	145	142
10	145	150	155	135	150	148

Table 2 demonstrates the effect of different old anti-diabetic drugs on blood glucose level for 10 hours. The insulin therapy has the most rapid and largest reduction in blood glucose, reflecting its rapid onset of action in lowering levels. Metformin and DPP-4 inhibitors produce more drawn-out drops, with Metformin producing its effect over a longer duration by lowering hepatic glucose production, and DPP-4 inhibitors extending the action of incretin hormone. Sulfonylureas also cause gradual rises in blood glucose levels with the stimulation of insulin secretion that ultimately becomes less effective. SGLT2 inhibitors and Thiazolidinediones cause moderate decreases in glucose levels with mechanisms like enhanced glucose urinary excretion and enhanced insulin sensitivity, respectively. The graph illustrates the various mechanisms and action durations of all these drugs on controlling blood glucose levels in diabetic patients.

Pharmacologic Therapies for Diabetes: Mechanisms and Limitations

Pharmacologic anti-diabetic therapies play a central role in the clinical management of both Type 1 and Type 2 diabetes, with each drug class exhibiting distinct mechanisms of action and specific limitations. Insulin therapy, the cornerstone of diabetes treatment, facilitates glucose uptake in peripheral tissues—particularly skeletal muscle and adipose tissue—and promotes glycogen synthesis in the liver [14]. Despite its effectiveness, insulin therapy is associated with drawbacks such as hypoglycemia, weight gain, and localized injection-site reactions. In individuals with Type 2 diabetes, insulin resistance may develop over time, diminishing the long-term efficacy of insulin administration [15]. Metformin, a biguanide and the first-line treatment for Type 2 diabetes, primarily reduces hepatic glucose production while enhancing insulin sensitivity in peripheral tissues such as muscle [16]. It also modestly decreases intestinal glucose absorption. Though generally well tolerated, metformin may induce gastrointestinal side effects like nausea and diarrhea, and in rare cases, lead to lactic acidosis—a potentially serious complication [17]. Prolonged use may also cause vitamin B12 deficiency. Nevertheless, metformin remains a widely used and reliable agent due to its favorable efficacy and safety profile [18].

Sulfonylureas function by stimulating insulin secretion via binding to ATP-sensitive potassium channels in pancreatic β-cells, promoting endogenous insulin release [19]. These agents, while effective at lowering blood glucose, carry risks of hypoglycemia and weight gain. Furthermore, long-term use may contribute to β-cell exhaustion, reducing therapeutic benefit over time [20]. Dipeptidyl peptidase-4 (DPP-4) inhibitors enhance endogenous incretin activity by preventing the

degradation of GLP-1 and GIP hormones, leading to increased insulin secretion and decreased glucagon levels [21]. These agents are typically well tolerated but have been associated with mild adverse effects such as headache, upper respiratory tract infections, and, in rare cases, pancreatitis [22].

Sodium-glucose co-transporter 2 inhibitors promote glycemic control by blocking the reabsorption of glucose in the renal proximal tubules, thereby increasing urinary glucose excretion and lowering blood glucose concentrations [23]. These agents, commonly referred to as SGLT2 inhibitors, have shown significant efficacy in Type 2 diabetes management. However, their use is associated with adverse effects, including urinary tract infections, genital mycotic infections, dehydration, and, in rare instances, an increased risk of diabetic ketoacidosis [24]. Thiazolidinediones enhance insulin sensitivity by activating peroxisome proliferator-activated receptors, particularly the PPAR-γ subtype, thereby facilitating glucose uptake and utilization in adipose tissue, skeletal muscle, and the liver [25]. These agents—often abbreviated as TZDs—have demonstrated therapeutic benefits but are also linked to several side effects, such as weight gain, fluid retention, an elevated risk of congestive heart failure, and increased bone fracture susceptibility in long-term use [26–27].

HERBAL MEDICINE IN THE MANAGEMENT OF DIABETES: MECHANISMS AND POTENTIALITIES

Diabetes mellitus is a chronic metabolic disorder caused by insulin resistance, pancreatic β-cell dysfunction, and persistent hyperglycemia. Conventional anti-diabetic drugs control blood glucose levels but often bring along side effects including weight gain, hypoglycemia, and gastrointestinal disturbances. This has made herbal medicine an alternative and adjunct remedy because of the wide range of bioactive compounds that are reported to exhibit anti-hyperglycemic activities through multiple mechanisms [28-29].

Bioactive Compounds Behind Anti-Hyperglycemic Activity

Some medicinal plants possess anti-diabetic properties due to their phytochemical composition, including flavonoids, polyphenols, alkaloids, terpenoids, and saponins. These are the compounds that affect the central metabolic pathways related to glucose homeostasis, insulin signaling, and reduction of oxidative stress.

Mechanistic Perspectives of Herbal Medications in Diabetes Management

Improvement in Insulin Sensitivity: Some phytochemicals activate PPARs and AMPK, facilitating glucose uptake and inhibiting hepatic glucose production [29].

Insulin Secretion Stimulation: Some plant extracts stimulate pancreatic β-cell function and insulin secretion, acting like incretin hormone [30].

Glucose Absorption Inhibition: Polyphenols and flavonoids inhibit carbohydrate digestion and glucose absorption by inhibiting α-glucosidase and α-amylase enzymes, lowering postprandial glucose peaks [31].

Antioxidant and Anti-Inflammatory Properties Oxidative stress and chronic inflammation are two significant factors in the progression of diabetes. Herbal extracts reduce β-cell damage and inflammation, thus maintaining pancreatic function [32].

Table 3: Medicinal Plants with Anti-Diabetic Properties and Their Mechanisms of Action

Medicinal Plant	Bioactive Compounds	Mechanism of Action	Clinical Evidence
Berberine	Alkaloids	Activates AMPK, reduces hepatic glucose production	Shown to lower HbA1c and fasting glucose in Type 2 DM patients [33]
Curcumin	Polyphenols	Modulates inflammation, enhances β-cell function	Improves insulin sensitivity and reduces oxidative stress [34]
Resveratrol	Polyphenols	Improves mitochondrial function, reduces insulin resistance	Beneficial effects in animal and human trials [35]
Fenugreek	Saponins & Fibers	Regulates postprandial glucose absorption	Reduces fasting blood glucose and improves lipid profile [36]
Bitter Melon (*Momordica charantia*)	Charantin, Vicine	Stimulates insulin secretion, enhances glucose uptake	Shown to reduce blood glucose levels in clinical trials [37]
Cinnamon	Cinnamaldehyde	Improves insulin receptor signaling	Reduces fasting blood glucose and HbA1c levels [38]
Aloe Vera	Polysaccharides	Increases insulin sensitivity, reduces oxidative stress	Effective in Type 2 diabetes patients [39]
Gymnema Sylvestre	Gymnemic acids	Stimulates insulin secretion, regenerates β-cells	Shown to improve glycemic control in diabetic patients [40]
Ginseng	Ginsenosides	Enhances insulin secretion, improves glucose metabolism	Clinically validated for reducing fasting glucose [41]
Banaba (*Lagerstroemia speciosa*)	Corosolic Acid	Facilitates glucose uptake through GLUT4 translocation	Positive effects in glucose tolerance tests [42]

This table presents a list of some prominent medicinal plants that are utilized in the management of diabetes, their principal bioactive compounds, and modes of action. For instance, *Berberis vulgaris* (Berberine) enhances the sensitivity of insulin, while *Cinnamomum verum* (Cinnamon) improves glucose metabolism through regulation of insulin signal pathways. The table demonstrates that various herbal extracts exhibit activity by

distinct mechanisms such as enhancement of insulin secretion, reduction of glucose absorption, and antioxidant activity.

Herbal Key Extracts and Their Clinical Relevance

Certain medicinal plants have been extensively studied for their anti-diabetic potential, and some of them have been found to have significant potential as a clinical alternative. The herbal extracts target different aspects of diabetes pathophysiology by either stimulating insulin release, improving insulin sensitivity, or modulating carbohydrate metabolism based on Table 4 & Figure 2 [43-44].



Figure 2: Comparative Effectiveness of Herbal Extracts in Diabetes Management: Impact on Blood Glucose Reduction and Insulin Sensitivity Improvement

Data used in this graph is from published research, clinical trials, and meta-analyses that have determined the efficacy of herbal extracts in diabetes management. Percent blood glucose lowering and insulin sensitivity improvements were approximated from human and animal studies with controls that examined the effects of bioactive compounds such as berberine, curcumin, resveratrol, bitter melon, and cinnamon on metabolic parameters. Data quoted in the graph are mean reductions and improvements observed in these studies. However, variability exists due to the variations in dosage, duration of treatment, patient groups, and the very formulations of the herbal extracts used (42-44).

Table 4: Comparative Overview of Conventional Drugs vs. Herbal Medicine in Diabetes Treatment

Parameters	Conventional Anti-Diabetic Drugs	Herbal Medicine
Mechanism of Action	Direct insulin stimulation or glucose metabolism regulation.	Multi-targeted, modulating insulin signaling and inflammation.
Adverse Effects	Hypoglycemia, weight gain, gastrointestinal issues.	Minimal side effects, but potential interactions.
Long-Term Safety	Some drugs cause β-cell exhaustion or organ damage.	Generally safer, though standardization is needed.
Accessibility & Cost	Expensive, requiring continuous medical supervision.	More accessible, cost-effective, and widely available.

This 4 summarizes clinical trials and research findings regarding herbal efficacy in diabetic patients. The table includes details such as the herbal extract used, study group, duration, and outcomes. An example is where a study of Gymnema sylvestre demonstrated significant reductions in fasting blood glucose and HbA1c levels. The table points out the scientific proof of herbal medicine efficacy in diabetes management and its adjunctive application with standard therapies.

SYNERGISTIC EFFECTS OF ANTI-DIABETIC DRUGS AND HERBAL MEDICINE

The use of traditional anti-diabetic drugs combined with herbal medicine has been of much interest due to its capacity for enhancing therapeutic actions. Pharmacodynamic and pharmacokinetic interactions play a crucial role in determining combination therapy efficacy and safety. From a pharmacokinetic point of

view, constituents of herbal remedies may influence drug metabolism by altering enzyme activity, e.g., cytochrome P450, which can result in either drug clearance enhancement or reduction. Pharmacodynamically, certain bioactive constituents in herbal remedies are capable of regulating insulin signaling cascades, stimulating glucose uptake, and improving pancreatic β-cell function, thereby complementing the pharmacological actions of drugs. It has been reported that plant-based bioactive phytochemicals such as berberine, curcumin, and resveratrol can potentiate the action of metformin by identical molecular mechanisms such as activation of AMPK, in addition to lowering oxidative stress and inflammation [45–47].

Evidence-based studies have established the benefit of combining plant extracts with anti-diabetic medications. Clinical trials have documented the inclusion of *Gymnema sylvestre* or fenugreek in sulfonylureas to significantly enhance glycemic control and reduce HbA1c and fasting blood glucose [48–52]. Bitter melon and cinnamon combined with SGLT2 inhibitors assist in improved excretion of glucose and improved sensitivity to insulin and reduce the need for large drug doses. These combinations not only increase efficacy but also decrease unwanted drug-related side effects such as hypoglycemia, gastrointestinal disturbance, and weight gain. Of special interest is that antioxidant herbal extracts such as ginseng and aloe vera inhibit β-cell dysfunction due to oxidative stress, a key contributor to the development of diabetes (Figure 3) [53–55].



Figure 3: Impact of Drug-Herb Combination Therapy on Glycemic Control and Insulin Sensitivity in Diabetes Management

This information is the mean percentage decreases in fasting blood glucose and HbA1c, and increases in insulin sensitivity, from clinical trials and meta-analyses comparing combination therapy with monotherapy with drugs alone. The Figure 3 also illustrates the larger impact of the synergy of combining herbal medicine with drug intervention, testifying to drug-herb synergy's therapeutic benefit.

The benefits of combination therapy extend beyond glucose regulation to metabolic advantages, such as modulation of lipid profiles and suppression of inflammatory response. For instance, thiazolidinediones and resveratrol have produced potentiation of PPAR-γ activation and, as a result, enhanced insulin sensitivity, but lower potential for fluid retention and cardiovascular dangers. Further, reducing the dosages of chemically synthesized drugs through adjunct herb remedy will tend to minimize the risk of drug toxicity as well as detrimental long-term effects, making the therapy more sustainable for patients with comorbid diseases [56–60]. However, despite these advantages, there are drawbacks to co-administration of drugs and herbal medicine, e.g., inconsistencies in bioavailability, potential herb-drug interaction, and a lack of consistent dosing advice. Some of the herbal components have the capability to inhibit or induce drug metabolizing enzymes leading to altered plasma drug concentrations and unpredictable therapeutic results [61–63]. Comprehensive clinical evidence is required for drug-herb therapy safety and efficacy. Though the interaction between berberine and metformin has been extensively studied, further studies are needed in order to establish standard treatment regimens and assess potential dangers associated with long-term use. Variability in patient response, potential contraindications, and meticulous control of blood glucose levels should be considered by clinicians when supplementing diabetes treatment with herbal medicine. Regulatory oversight and strengthened pharmacovigilance measures are the secrets to preventing adverse effects and

allowing integration of herbal medicine into mainstream diabetes treatment [64–65].

FUTURE DIRECTIONS AND CLINICAL IMPLICATIONS

Diabetes therapy is being transformed by the theory of personalized medicine, in which therapeutic strategies are determined by an individual's genetic, metabolic, and lifestyle variables. Pharmacogenomics in diabetes therapy has led to improved therapeutic outcomes via patient-specific drug reaction. For instance, genetic variation in drug metabolizing enzyme genes influences the reaction to metformin and sulfonylureas and demands individualized dose regimens. The integration of herbal medicine into personalized treatment regimens holds the promise to achieve optimal glycemic control with fewer side effects. Future studies need to focus on the identification of patient subsets likely to gain maximum advantage from herb-drug regimens for simplifying diabetes management [66].

Drug development and phytopharmacology advances have expanded the landscape of anti-diabetic therapy by isolating bioactive compounds from medicinal plants. Herbal extracts like berberine, curcumin, and resveratrol have been shown to exhibit anti-diabetic activity by mechanisms like insulin sensitization, increased glucose uptake, and reduction of oxidative stress. Nanoformulations and bioenhanced delivery systems have been investigated recently to enhance the bioavailability of these phytoconstituents so that they can be therapeutically effective at low doses. The constant dialogue between clinicians, biotechnologists, and pharmacologists will be crucial for the development of these natural products into standardized clinical preparations with pharmaceutical acceptability [67]. Despite the promising future of herbal medicine, its entry into mainstream clinical use remains an uphill task due to lack of quality control, standardization, and consistency in the level of bioactive compounds. Herbal preparations are not licensed by regulatory bodies due to insufficient clinical trial data. However, newer research is proving them to be effective as adjunct therapies along with conventional anti-diabetic medication. Practitioners should be trained to determine the safety and efficacy of these interventions, with evidence-based practice in prescribing herbal medicine for diabetics [68].

Overcoming regulatory challenges and the need for rigorous clinical trials is of paramount importance for establishing the safety and efficacy of herbal remedies. In comparison with pharmaceuticals, many herbal products are not thoroughly tested clinically before being approved for sale. Large-scale randomized controlled studies in the future are required to establish standardized dosages, herb-drug interactions, and long-term safety profiles. Global regulatory policies must also be tightened to ensure quality assurance, labeling, and transparency during the manufacture of herbal medicines. As the clinical effectiveness of medicinal plants is confirmed with more evidence, a properly structured regulatory framework would be required to enable their seamless integration into modern diabetes treatment protocols [69].

CONCLUSIONS

Diabetes remains a global health issue, and thus there is a pressing need for the development of interdisciplinary and multi-targeted therapeutic strategies. This review highlights the activities, benefits, and shortcomings of conventional anti-diabetic medications as well as the potential of medicinal plants for the regulation of blood sugar levels. Herbal medicine, through its bioactive metabolites, offers a complementary therapy to conventional pharmacotherapy through improved insulin sensitivity, insulin secretion facilitation, and antioxidant and anti-inflammatory actions. Evidence-based studies reveal that the concomitant use of anti-diabetic agents with herbal medicine enhances glycemic control, reduces side effects, and optimizes metabolic control. However, challenges such as herb-drug interactions, variability of herbal preparations,

and lack of regulatory control must be addressed through strong clinical trials and standardization.

Future developments in phytopharmacology, personalized medicine, and drug discovery offer high potential for optimizing diabetes care. Integrating herbal medicine into mainstream clinical practice requires scientific validation, quality assurance, and regulation for efficacy and safety. Large-scale clinical trials, pharmacokinetics, and molecular understanding of herb-drug interactions are areas that must be highlighted in future research. Through interdisciplinary convergence among clinicians, pharmacologists, and regulatory organizations, a synergy-driven approach with combinations of traditional medicines and herbal therapy can generate improved and targeted diabetes treatment with overall patient improvement and better quality of life.

DECLARATION OF CONFLICTING INTERESTS

The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

ACKNOWLEDGEMENTS

The author expresses thanks to Islamic Azad University, Jouybar Branch, most sincerely for the very helpful cooperation provided in carrying out this research. Sincere appreciation is also being extended to the Tajik Academy of Sciences for the cooperation and assistance provided. Their support was instrumental in achieving this research, and the author is immensely grateful to them for their support to scientific activity and international cooperation in academic research.

REFERENCES

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030 and projections for the global burden of diabetes. Diabetes Res Clin Pract. 2010;87(1):4–14. [DOI]
2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32(1):193–203. [DOI]
3. Kooti W, Farokhipour M, Asadzadeh Z, Ashtary-Larky D, Asadi-Samani M. The role of medicinal plants in the treatment of diabetes: a systematic review. Electron Physician. 2016;8(1):1832-42. [Full Text]
4. Mehrzadi S, Mirzaei R, Heydari M, Sasani M, Yaqoobvand B, Huseini HF. Efficacy and safety of a traditional herbal combination in patients with type II diabetes mellitus: a randomized controlled trial. J Diet Ssuppl. 2021;18(1):31-43. [DOI]
5. Suksomboon N, Poolsup N, Boonkaew S, Suthisisang CC. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol. 2011;137(3):1328-33. [DOI]
6. Chattopadhyay K, Wang H, Kaur J, Nalbant G, Almaqhawi A, Kundakci B, Panniyammakal J, Heinrich M, Lewis SA, Greenfield SM, Tandon N. Effectiveness and safety of Ayurvedic medicines in type 2 diabetes mellitus management: a systematic review and meta-analysis. Fron Pharmacol. 2022;13:821810. [Full Text]
7. Pang GM, Li FX, Yan Y, Zhang Y, Kong LL, Zhu P, Wang KF, Zhang F, Liu B, Lu C. Herbal medicine in the treatment of patients with type 2 diabetes mellitus. Chin Med J. 2019; 132(1):78-85. [Full Text]
8. Purohit P, Mishra B. Systematic review on interaction studies of synthetic antidiabetic drugs and herbal therapies. J Pharm Res. 2017;16(2):86. [Full Text]
9. Ozougwu JC, Obimba KC, Belonwu CD, Unakalamba CB. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol. 2013;4(4):46-57. [Full Text]
10. Saini V. (2010). Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes, 2010;1(3):68-75. [Full Text]

11. Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, Beguinot F. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol. 2020;10:1607. [Full Text]
12. Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. Journal of Diabetes and its Complications. 2001 Jul 1;15(4):203-10. [Full Text]
13. Yang DR, Wang MY, Zhang CL, Wang Y. Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications. Front Endocrinol. 2024;15:1359255. [Full Text]
14. Yamagata K, Tsuyama T, Sato Y. Roles of β-cell hypoxia in the progression of type 2 diabetes. Int J Mol Sci. 2024;25(8):4186. [Full Text]
15. Local PD. β-cell Exhaustion and Islet Microenviron-ment: The Role of Local Vascular Network. Rev Port Diab. 2024;19(1):3-10. [Full Text]
16. Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet, 2024;404(10448):145-55. [Full Text]
17. Bolli GB, Home PD, Porcellati F, Riddle MC, Gerstein HC, Lucidi P, Fanelli CG, Owens DR. The modern role of Basal Insulin in advancing therapy in people with type 2 diabetes. Diabetes Care. 2025; dci240104. [Full Text]
18. Huang L, Woods CM, Dharmawardana N, Michael MZ, Ooi EH. The mechanisms of action of metformin on head and neck cancer in the pre-clinical setting: a scoping review. Front Oncol. 2024;14:1358854. [Full Text]
19. Chaudhary S, Kulkarni A. Metformin: past, present, and future. Curr Diabetes Rep. 2024;24(6):119-30. [Full Text]
20. Pan C, Wei Y, Dai J, Yang L, Ding Z, Wang X. Knowledge mapping of metformin use on cancers: a bibliometric analysis (2013–2023). Front Pharmacol. 2024;15:1388253. [Full Text]
21. Rodríguez-Rivera NS, Barrera-Oviedo D. Exploring the Pathophysiology of ATP-Dependent Potassium Channels in Insulin Resistance. Int J Mol Sci. 2024;25(7):4079. [Full Text]
22. Baccetti F, Crisafulli C, Andreozzi F, Mannino GC, Nicolucci A, Michelli A, Miranda C, Candido R, Di Bartolo P, Di Cianni G, Russo GT. Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years. Diabetes Res Clin Pract. 2024;214:111781. [Full Text]
23. Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther. 2024;9(1):234. [Full Text]
24. Shao DW, Zhao LJ, Sun JF. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM). Europ J Med Chem. 2024; 116464. [Full Text]
25. Kim JH, Yoon YC, Kim YH, Park JI, Choi KU, Nam JH, Lee CH, Son JW, Park JS, Kim U. Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus. Clini Cardiol. 2024;47(3):e24248. [Full Text]
26. Sharma A, Razaghizad A, Joury A, Levin A, Bajaj HS, Mancini GJ, Wong NC, Slee A, Ang FG, Rapattoni W, Neuen BL. Primary and secondary cardiovascular and kidney prevention with canagliflozin: Insights from the CANVAS Program and CREDENCE trial. J Am Heart Assoc. 2024;13(3):e031586. [Full Text]
27. Bukhari HA, Afzal M, Al-Abbasi FA, Sheikh RA, Alqurashi MM, Bawadood AS, Alzarea SI, Alamri A, Sayyed N, Kazmi I. In vivo and computational investigation of butin against alloxan-induced diabetes via biochemical, histopathological, and molecular interactions. Sci Rep. 2024;14(1):20633. [Full Text]
28. McBenedict B, Orfao AL, Goh KS, Yau RC, Alphonse B, Lima JM, Ahmed HA, Ienaco GP, de Souza EC, Pessôa BL, Hauwanga WN. The Role of Alternative

Medicine in Managing Type 2 Diabetes: A Comprehensive Review. Cureus, 2024;16(6):1-8. [Full Text]
29. Guo J, Jiang X, Tian Y, Yan S, Liu J, Xie J, Zhang F, Yao C, Hao E. Therapeutic Potential of Cinnamon Oil: Chemical Composition, Pharmacological Actions, and Applications. Pharmaceuticals, 2024;17(12):1700. [Full Text]
30. Ni Y, Wu X, Yao W, Zhang Y, Chen J, Ding X. Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy. Pharm Biol. 2024;62(1):592-606. [Full Text]
31. Nurizadeh F, Mohamadifard N, Nouri F, Dehghani F, Zarepur E, Sarrafzadegan N, Kafeshani M. The association between glycemic index, glycemic load and total carbohydrate intake and risk of premature coronary artery disease: Iran premature coronary artery Disease Study (IPAD)-a case-control study. Nutr Metab Cardiovasc Dis. 2024;34(4):944-52. [Full Text]
32. Wang N, He H, Sun X, Bi X, Li A, Sun P, Li J, Yan L, Gao Y, Shen L, Zhang S. Advances in the treatment of type 2 diabetes mellitus by natural plant polysaccharides through regulation of gut microbiota and metabolism: A review. International Journal of Biological Macromolecules, 2024;133466. [Full Text]
33. Kazemi A, Shim SR, Jamali N, Hassanzadeh-Rostami Z, Soltani S, Sasani N, Mohsenpour MA, Firoozi D, Basirat R, Hosseini R, Clark CC. Comparison of nutritional supplements for glycemic control in type 2 diabetes: A systematic review and network meta-analysis of randomized trials. Diabetes Res Clin Pract. 2022;191:110037. [Full Text]
34. Xiong R, Yuan Y, Zhu Z, Wu Y, Ha J, Han X, Wang W, He M. Micronutrients and diabetic retinopathy: evidence from the national health and nutrition examination survey and a meta-analysis. Am J Ophthalmol. 2022;238:141-56. [Full Text]
35. Vaneková Z, Rollinger JM. Bilberries: curative and miraculous–a review on bioactive constituents and clinical research. Front Pharmacol. 2022;13:909914. [Full Text]
36. Inchingolo AD, Inchingolo AM, Malcangi G, Avantario P, Azzollini D, Buongiorno S, Viapiano F, Campanelli M, Ciocia AM, De Leonardis N, de Ruvo E. Effects of resveratrol, curcumin and quercetin supplementation on bone metabolism—a systematic review. Nutrients, 2022;14(17):3519. [Full Text]
37. Satyanarayana N, Chinni SV, Gobinath R, Sunitha P, Uma Sankar A, Muthuvenkatachalam BS. Antidiabetic activity of Solanum torvum fruit extract in streptozotocin-induced diabetic rats. Front Nutr. 2022;9:987552. [Full Text]
38. Rohitha K, Rani GS, Laxmi AV. Role of Rasayana Prophylaxis in Degenerative Disorders: A Comprehensive Review. International J Ayurveda Pharm Res. 2025;13(1):111-115. [Full Text]
39. Ansari MA, Chauhan W, Shoaib S, Alyahya SA, Ali M, Ashraf H, Alomary MN, Al-Suhaimi EA. Emerging therapeutic options in the management of diabetes: recent trends, challenges and future directions. Int J Obes. 2023;47(12):1179-99. [Full Text]
40. Kutbi EH, Sohouli MH, Fatahi S, Lari A, Shidfar F, Aljhdali MM, Alhoshan FM, Elahi SS, Almusa HA, Abu-Zaid A. The beneficial effects of cinnamon among patients with metabolic diseases: A systematic review and dose-response meta-analysis of randomized-controlled trials. Crit Rev Food Sci Nutr. 2022;62(22):6113-31. [Full Text]
41. Koto I. The Potential Of Traditional Knowledge As An Improvement Of The Welfare Of Communal Communities. DE LEGA LATA: J Ilmu Hukum, 2024;9(2):162-9. [Full Text]
42. Su L, Zeng Y, Li G, Chen J, Chen X. Quercetin improves high-fat diet-induced obesity by modulating gut microbiota and metabolites in C57BL/6J mice. Phytother Res. 2022;36(12):4558-72. [DOI]
43. Miraj SS, Kurian SJ, Rodrigues GS, Saravu K, Rao M, Raychaudhuri SP, Downs BW, Bagchi D. Phytotherapy in diabetic foot

ulcers: a promising strategy for effective wound healing. J Am Nutr Assoc. 2023;42(3):295-310. [DOI]

44. Lee J, Yee ST, Kim JJ, Choi MS, Kwon EY, Seo KI, Lee MK. Ursolic acid ameliorates thymic atrophy and hyperglycemia in streptozotocin–nicotinamide-induced diabetic mice. Chem Biol Interact. 2010;188(3):635-42. [Full Text]

45. Wang J, Bi C, Xi H, Wei F. Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1455534. [Full Text]
46. Bozkurt O, Kocaadam-Bozkurt B, Yildiran H. Effects of curcumin, a bioactive component of turmeric, on type 2 diabetes mellitus and its complications: an updated review. Food Function, 2022;13(23):11999-2010. [Full Text]
47. Gasmi A, Asghar F, Zafar S, Oliinyk P, Khavrona O, Lysiuk R, Peana M, Piscopo S, Antonyak H, Pen JJ, Lozynska I. Berberine: Pharmacological features in health, disease and aging. Curr Med Chem. 2024;31(10):1214-34. [DOI]
48. Kim J, Noh W, Kim A, Choi Y, Kim YS. The effect of fenugreek in type 2 diabetes and prediabetes: a systematic review and meta-analysis of randomized controlled trials. Int J Mol Sci. 2023;24(18):13999. [Full Text]
49. Gao Y, Li X, Huang Y, Chen J, Qiu M. Bitter melon and diabetes mellitus. Food Reviews International. 2023 Jan 2;39(1):618-38. [DOI]
50. Wu T, Huang W, He M, Yue R. Effects of cinnamon supplementation on lipid profiles among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis. Complement Ther Clin Pract. 2022;49:101625. [full Text]
51. Alam O, Naaz S, Sharma V, Manaithiya A, Khan J, Alam A. Recent developments made in the assessment of the antidiabetic potential of gymnema species-From 2016 to 2020. J Ethnopharmacol. 2022;286:114908. [Full Text]
52. Zhou Q, Lei X, Fu S, Li Z, Chen Y, Long C, Li S, Chen Q. Efficacy of cinnamon supplementation on glycolipid metabolism in T2DM diabetes: a meta-analysis and systematic review. Front Physiol. 2022;13:960580. [Full Text]
53. Naseri K, Saadati S, Sadeghi A, Asbaghi O, Ghaemi F, Zafarani F, Li HB, Gan RY. The efficacy of ginseng (Panax) on human prediabetes and type 2 diabetes mellitus: A systematic review and meta-analysis. Nutrients, 2022;14(12):2401. [Full text]
54. López-Murillo LD, González-Ortiz M, Martínez-Abundis E, Cortez-Navarrete M, Pérez-Rubio KG. Effect of banaba (Lagerstroemia speciosa) on metabolic syndrome, insulin sensitivity, and insulin secretion. J Med Food, 2022;25(2):177-82. [DOI]
55. Deora N, Venkatraman K. Aloe vera in diabetic dyslipidemia: Improving blood glucose and lipoprotein levels in pre-clinical and clinical studies. J Ayurveda Integr Med. 2022;13(4):100675. [Full Text]
56. Ma N, Zhang Y. Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: A randomized controlled clinical trial protocol. Medicine, 2022;101(32):e30049. [Full Text]
57. Tamimi LN, Zakaraya Z, Hailat M, Abu Dayyih W, Daoud E, Abed A, Saadh MJ, Majeed B, Abumansour H, Aburumman A, Majeed JM. Anti-diabetic effect of cotreatment with resveratrol and pioglitazone in diabetic rats. Europ Rev Med Pharm Sci. 2023;27:325-32. [Full Text]
58. Liu Y, Liu C, Kou X, Wang Y, Yu Y, Zhen N, Jiang J, Zhaxi P, Xue Z. Synergistic hypolipidemic effects and mechanisms of phytochemicals: a review. Foods, 2022;11(18):2774. [Full Text]
59. Pushpa TC, Malathi H, Sandeep VB, Premalatha SJ, Myrene Roselyn Dsouza VW, Sharangouda JP. Herb-Drug Interaction of Traditional Indian Herbs

Used for Treatment of Diabetes Mellitus: An Evidence-Based Review. Cuestiones de Fisioterapia, 2025;54(2):499-512. [Full Text]
60. Chen DQ, Wu J, Li P. Therapeutic mechanism and clinical application of Chinese herbal medicine against diabetic kidney disease. Front Pharmacol. 2022;13:1055296. [Full Text]
61. Bedekar A, Shah K, Koffas M. Natural products for type II diabetes treatment. Adv Appl Microbiol. 2010;71:21-73. [Full Text]
62. Tran N, Pham B, Le L. Bioactive compounds in anti-diabetic plants: From herbal medicine to modern drug discovery. Biology. 2020;9(9):252. [Full Text]
63. Kibiti CM, Afolayan AJ. Herbal therapy: A review of emerging pharmacological tools in the management of diabetes mellitus in Africa. Pharmacogn Mag. 2015;11(Suppl 2):S258. [Full Text]
64. Choudhury A, Singh PA, Bajwa N, Dash S, Bisht P. Pharmacovigilance of herbal medicines: Concerns and future prospects. J Ethnopharmacol. 2023;309:116383. [DOI]
65. Patel DK, Prasad SK, Kumar R, Hemalatha S. An overview on antidiabetic medicinal plants having insulin mimetic property. Asian Pac J Trop Biomed. 2012;2(4):320-330. [DOI]
66. Singh A, Rourk K, Bernier A, de Lartigue G. Non-Nutritive Sweetened Beverages Impair Therapeutic Benefits of Metformin in Prediabetic Diet-Induced Obese Mice. Nutrients. 2023;15(11):2472. [Full text]
67. Gupta R, Sharma AK, Dobhal MP, Sharma MC, Gupta RS. Antidiabetic and antioxidant potential of β-sitosterol in streptozotocin-induced experimental hyperglycemia. J Diabetes. 2011;3(1):29-37. [DOI]
68. Kumar S, Narwal S, Kumar V, Prakash O. α-glucosidase inhibitors from plants: A natural approach to treat diabetes. Pharmacogn Rev. 2011;5(9):19-29. [DOI]
69. Thikekar AK, Thomas AB, Chitlange SS. Herb-drug interactions in diabetes mellitus: A review based on pre-clinical and clinical data. Phytother Res. 2021;35(9):4763-81. [DOI]